Human CellExp IL-29, Human recombinant protein
Human Cellexp Human Recombinant IL-29
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8IU54 |
---|---|
Calculated MW | 29 and 35 kDa, monomer, glycosylated |
Gene ID | 282618 |
---|---|
Gene Symbol | IFNL1 |
Other Names | Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21. |
Gene Source | Human |
Source | Human 293 cell expressed |
Assay&Purity | SDS-PAGE; > 95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | 0.5 to 5 ng/ml |
Application Notes | Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin. |
Format | Lyophilized |
Storage | -80°C; Lyophilized in PBS. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor β (IL10RB) and interleukin 28 receptor α. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumor activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues.
References
Sheppard P.,et al.Nat. Immunol. 4:63-68(2003).
Kotenko S.V.,et al.Nat. Immunol. 4:69-77(2003).
Li M.,et al.Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
Grimwood J.,et al.Nature 428:529-535(2004).
Donnelly R.P.,et al.J. Interferon Cytokine Res. 30:555-564(2010).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.